CD8+ T cells from relapsed/refractory AML patients had a higher degree of clonal hyperexpression associated with terminal differentiation and with a higher CD8-derived signature correlated with poorer outcomes in untreated AML patients [143]. This evidence concerns the gene CD8A and acute myeloid leukemia.